Annexon Inc (ANNX) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03589W1027
Medicines, Antibody, Fragment, Inhibitor
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. Web URL: https://www.annexonbio.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
ANNX Stock Overview
Market Cap in USD | 423m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2020-07-24 |
ANNX Stock Ratings
Growth 5y | -3.83 |
Fundamental | -83.4 |
Dividend | - |
Rel. Performance vs Sector | -2.90 |
Analysts | 4.63/5 |
Fair Price Momentum | 4.59 USD |
Fair Price DCF | - |
ANNX Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
ANNX Growth Ratios
Growth 12m | -29.36% |
Growth Correlation 12m | 32% |
Growth Correlation 3m | -20% |
CAGR 5y | -30.19% |
CAGR/Mean DD 5y | -0.46 |
Sharpe Ratio 12m | -0.30 |
Alpha vs SP500 12m | -53.45 |
Beta vs SP500 5y weekly | 0.78 |
ValueRay RSI | 26.22 |
Volatility GJR Garch 1y | 73.87% |
Price / SMA 50 | -17.73% |
Price / SMA 200 | 17.8% |
Current Volume | 2955.7k |
Average Volume 20d | 1892.9k |
External Links for ANNX Stock
News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of ANNX stocks?
As of May 16, 2024, the stock is trading at USD 4.50 with a total of 2,955,662 shares traded.
Over the past week, the price has changed by -7.60%, over one month by -21.60%, over three months by -13.63% and over the past year by -25.74%.
As of May 16, 2024, the stock is trading at USD 4.50 with a total of 2,955,662 shares traded.
Over the past week, the price has changed by -7.60%, over one month by -21.60%, over three months by -13.63% and over the past year by -25.74%.
What is the forecast for ANNX stock price target?
According to ValueRays Forecast Model, ANNX Annexon Inc will be worth about 5.1 in May 2025. The stock is currently trading at 4.50. This means that the stock has a potential upside of +12.44%.
According to ValueRays Forecast Model, ANNX Annexon Inc will be worth about 5.1 in May 2025. The stock is currently trading at 4.50. This means that the stock has a potential upside of +12.44%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 15.6 | 247 |
Analysts Target Price | 15.6 | 247 |
ValueRay Target Price | 5.1 | 12.4 |